Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with endocrine therapy, has demonstrated substantial efficacy in extending progression-free survival (PFS) for women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. This conclusion comes from a release of subgroup analyses from the […]
Novartis has announced that the European Commission has expanded the approval of its multiple sclerosis drug, Gilenya (fingolimod), to include the treatment of children and adolescents aged 10 to 17 years with relapsing-remitting multiple sclerosis. This approval marks Gilenya as the first oral disease-modifying therapy authorized for this younger demographic in Europe. Pioneering oral therapy […]
In a significant step towards expanding biosimilar access, Pfizer and AbbVie have resolved all global intellectual property disputes concerning Pfizer’s proposed biosimilar to AbbVie’s blockbuster rheumatoid arthritis drug, Humira (adalimumab). This agreement marks a major milestone in Pfizer’s mission to broaden its portfolio of biosimilar medications, as it acquires a non-exclusive patent license to market […]
In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval for its pioneering gene therapy, Luxturna (voretigene neparvovec). Targeted at both children and adults, Luxturna addresses vision impairment caused by a rare, inherited retinal dystrophy associated with biallelic RPE65 mutations. This long-awaited approval now extends the gene […]
The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Novartis’ Promacta (eltrombopag), approving it for use in the first-line treatment of severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy (IST). This approval extends to both adult and pediatric patients aged two years and older. Promacta’s New FDA Approval: Enhancing […]
The European Commission (EC) has granted Novartis approval for a significant update to the label of its psoriatic arthritis treatment, Cosentyx (secukinumab). This update introduces new dosing flexibility, allowing for administration of up to 300mg based on individual clinical response. This development provides clinicians with enhanced options to tailor treatments for their patients suffering from […]
Novartis acquisition of Endocyte : US biopharma company Endocyte has agreed to be acquired by Swiss pharma company Novartis in a deal worth around $2.1 billion. As per the latest pharma acquisition news, Novartis has gone ahead with the deal to enlarge its expertise in radiopharmaceuticals for treating various types of cancers. Novartis Acquisition of […]
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s capabilities in radiopharmaceuticals, particularly for cancer treatment. The acquisition will see Novartis purchase all outstanding shares of Endocyte at $24 per share. Expanding Expertise in Radiopharmaceuticals Endocyte specializes in developing […]
Aurobindo Pharma, a prominent Indian pharmaceutical company, has agreed to a significant acquisition from Sandoz US, a division of the Swiss pharmaceutical giant Novartis. The deal, valued at approximately $1 billion, involves the purchase of Sandoz’s dermatology business and a diverse portfolio of oral solid products, along with commercial and manufacturing infrastructure. The transaction terms […]
In a strategic move within the pharmaceutical industry, Sandoz US, a subsidiary of the Swiss-based Novartis, has announced the sale of its dermatology and oral solids businesses to Aurobindo Pharma, an Indian pharmaceutical giant. The deal, which includes a $900 million cash payment and potential earn-outs of $100 million, marks a significant reshaping of Sandoz’s […]
